1-[(1-Methylpyrrolidin-3-yl)methyl]piperazine | 933687-95-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-[(1-Methylpyrrolidin-3-yl)methyl]piperazine
• CAS: 933687-95-7
• 化学式: C₁₀H₂₁N₃
• 分子量: 183.29
• InChiKey: OXDRSJCDAHMHNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF
  申请人：Tabomedex Biosciences, LLC

  公开号：US20170190713A1

  公开（公告）日：2017-07-06

  Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.

  本文提供了作为MK2抑制剂有用的替代融合四环化合物。本发明还提供了所述化合物的药物组合物。本发明还提供了替代融合四环化合物的医药用途。
• Compositions and methods for treatment of diabetic retinopathy
  申请人：NOVARTIS AG

  公开号：US10960087B2

  公开（公告）日：2021-03-30

  The present invention provides compounds and methods for the treatment of diabetic retinopathy. In particular, LFA-1 antagonists are described herein to be used in the treatment of diabetic retinopathy. One aspect of the invention provides for diagnosis of diabetic retinopathy and administration of a LFA-1 antagonist, after the patient is diagnosed with diabetic retinopathy.

  本发明提供了用于治疗糖尿病视网膜病变的化合物和方法。特别是，本文描述了用于治疗糖尿病视网膜病变的 LFA-1 拮抗剂。本发明的一个方面提供了糖尿病视网膜病变的诊断，以及在患者被诊断为糖尿病视网膜病变后给予 LFA-1 拮抗剂。
• COMPOSITIONS AND METHODS FOR TREATMENT
  申请人：SARCODE BIOSCIENCE INC.

  公开号：US20170143692A1

  公开（公告）日：2017-05-25

  The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
• COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY
  申请人：Novartis AG

  公开号：US20210338839A1

  公开（公告）日：2021-11-04

  The present invention provides compounds and methods for the treatment of diabetic retinopathy. In particular, LFA-1 antagonists are described herein to be used in the treatment of diabetic retinopathy. One aspect of the invention provides for diagnosis of diabetic retinopathy and administration of a LFA-1 antagonist, after the patient is diagnosed with diabetic retinopathy.
• [EN] FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSÉS QUADRACYCLIQUES CONDENSÉS, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
  申请人：TABOMEDEX BIOSCIENCES LLC

  公开号：WO2017120164A1

  公开（公告）日：2017-07-13

  Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.